AbbVie Q4: Skyrizi & Rinvoq Drive 2026 Outlook Now

AbbVie ends 2025 with Skyrizi- and Rinvoq-powered momentum

AbbVie (ABBV), a core S&P 500 healthcare name, closed its 2025 fiscal year with clear evidence that its post-Humira transition is on track. The company’s Q4 and full-year results (reported Feb 4, 2026) delivered double-digit growth in immunology and strong gains in neuroscience, even as aesthetic products softened and the stock experienced a modest pullback later in February. For investors, the numbers clarify where AbbVie’s near-term earnings power lies and where watchfulness is still required.

Latest financial snapshot

Top-line and EPS highlights

Full-year 2025 revenue: $61.16 billion, up 8.6% year-over-year (8.5% operationally). On a GAAP basis, diluted EPS was reported at $2.36; adjusted diluted EPS (excluding certain IPR&D and milestone items) came in at $10.00 for the period.

Segment performance (FY2025)

• Immunology: $30.406 billion (+14.0%). Skyrizi drove the majority of the growth, contributing $17.562 billion. Rinvoq added $8.304 billion.
• Neuroscience: $10.767 billion (+19.6%), signaling robust demand in CNS therapies.
• Oncology: $6.655 billion (+1.5%).
• Aesthetics: $4.860 billion (–6.1%); Botox Cosmetic totaled $2.602 billion and Juvederm $993 million, showing softness relative to AbbVie’s other franchises.

Management issued forward adjusted EPS guidance for 2026 in the range of $14.37 to $14.57, providing investors with concrete expectations for the coming year.

Market reaction and trading context

On February 19, 2026, AbbVie’s share price declined roughly 1.9% to $224.35, underperforming some peers during a mildly down session for broad indices. Trading volume that day was about 5.3 million shares versus a 50-day average of ~6.7 million, indicating muted conviction behind the move. The stock was about 8.4% below its 52-week high of $244.81 (October 1, 2025).

What the price action suggests

The combination of a modest sell-off and below-average volume points to short-term digestion rather than a broad-based sell signal. Investors often take profits after sizable run-ups; when that profit-taking happens on lighter volume, it frequently reflects hesitation and reassessment rather than capitulation.

Investor implications — clarity and caution

Two straightforward conclusions emerge from AbbVie’s most recent reporting:

• Clear growth engines: Skyrizi and Rinvoq are not theoretical replacements for Humira—they are real revenue drivers. Together they accounted for roughly 26 billion in revenue last year, underpinning the company’s immunology strength and helping to offset legacy declines.
• Areas to monitor: Aesthetics remains a weak spot and could pressure near-term top-line momentum if the category does not stabilize. Market sensitivity to guidance, product launches, or unexpected trial outcomes will also move sentiment.

Think of AbbVie’s portfolio like a fleet where older ships are being replaced by newer, faster vessels: the new ships (Skyrizi, Rinvoq, neuroscience assets) are proving capable of carrying the fleet’s overall load, but any storm hitting a single vessel (weaker aesthetics) still demands attention from the captain and crew.

Bottom line

AbbVie’s FY2025 results provide tangible evidence that its strategy to pivot beyond Humira is yielding results, with Skyrizi and Rinvoq powering robust immunology growth and neuroscience contributing meaningful upside. Management’s explicit 2026 adjusted EPS guidance adds clarity for investors. Near-term share weakness after the earnings cycle appears to reflect digestion rather than a material change in the company’s trajectory, but continued monitoring of aesthetics and execution against guidance is warranted.

For investors focused on S&P 500 healthcare exposure, AbbVie presents a blend of high cash generation and visible growth drivers—paired with the usual biopharma operational risks that merit active monitoring.